TY - JOUR
T1 - Orbital Lymphoma—An International Multicenter Retrospective Study
AU - Olsen, Tine Gadegaard
AU - Holm, Frederik
AU - Mikkelsen, Lauge Hjorth
AU - Rasmussen, Peter Kristian
AU - Coupland, Sarah E.
AU - Esmaeli, Bita
AU - Finger, Paul T.
AU - Graue, Gerardo F.
AU - Grossniklaus, Hans E.
AU - Honavar, Santosh G.
AU - Khong, Jwu Jin
AU - McKelvie, Penelope A.
AU - Mulay, Kaustubh
AU - Sjö, Lene Dissing
AU - Vemuganti, Geeta K.
AU - Thuro, Bradley A.
AU - Heegaard, Steffen
N1 - Funding Information:
Funding/Support: This study was supported by grants from Synoptik-Fonden , Copenhagen, Denmark, and Fight for Sight Denmark, Copenhagen, Denmark. The funding sources played no role in the design of the study; collection, analysis, and interpretation of data; in writing of the report; or in the decision to submit the article for publication. Financial Disclosures: The following authors have no financial disclosures: Tine Gadegaard Olsen, Frederik Holm, Lauge Hjorth Mikkelsen, Peter Kristian Rasmussen, Sarah E. Coupland, Bita Esmaeli, Paul T. Finger, Gerardo F. Graue, Hans E. Grossniklaus, Santosh G. Honavar, Jwu Jin Khong, Penelope A. McKelvie, Kaustubh Mulay, Lene Dissing Sjö, Geeta K. Vemuganti, Bradley A. Thuro, and Steffen Heegaard. All authors attest that they meet the current ICMJE criteria for authorship.
Funding Information:
Funding/Support: This study was supported by grants from Synoptik-Fonden, Copenhagen, Denmark, and Fight for Sight Denmark, Copenhagen, Denmark. The funding sources played no role in the design of the study; collection, analysis, and interpretation of data; in writing of the report; or in the decision to submit the article for publication. Financial Disclosures: The following authors have no financial disclosures: Tine Gadegaard Olsen, Frederik Holm, Lauge Hjorth Mikkelsen, Peter Kristian Rasmussen, Sarah E. Coupland, Bita Esmaeli, Paul T. Finger, Gerardo F. Graue, Hans E. Grossniklaus, Santosh G. Honavar, Jwu Jin Khong, Penelope A. McKelvie, Kaustubh Mulay, Lene Dissing Sjö Geeta K. Vemuganti, Bradley A. Thuro, and Steffen Heegaard. All authors attest that they meet the current ICMJE criteria for authorship.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/3
Y1 - 2019/3
N2 - Purpose: To investigate and characterize the clinical features of subtype-specific orbital lymphoma. Design: Retrospective, interventional case series. Methods: The study included 7 international eye cancer centers. Patient data were collected from January 1, 1980 through December 31, 2017. A total of 797 patients with a histologically verified orbital lymphoma were included. The primary endpoints were overall survival, disease-specific survival, and progression-free survival. Results: The median age was 64 years, and 51% of patients (n = 407) were male. The majority of lymphomas were of B-cell origin (98%, n = 779). Extranodal marginal zone B-cell lymphoma (EMZL) was the most frequent subtype (57%, n = 452), followed by diffuse large B-cell lymphoma (DLBCL) (15%, n = 118), follicular lymphoma (FL) (11%, n = 91), and mantle cell lymphoma (MCL) (8%, n = 66). Localized Ann Arbor stage IE EMZL and FL were frequently treated with external beam radiation therapy. DLBCL, MCL, and disseminated EMZL and FL were primarily treated with chemotherapy. EMZL and FL patients had a markedly better prognosis (10-year disease-specific survival of 92% and 71%, respectively) than DLBCL and MCL patients (10-year disease-specific survival of 41% and 32%, respectively). Conclusions: Four lymphoma subtypes were primarily found in patients with orbital lymphoma: EMZL, DLBCL, FL, and MCL. The histologic subtype was found to be the main predictor for outcome, with EMZL and FL patients having a markedly better prognosis than DLBCL and MCL.
AB - Purpose: To investigate and characterize the clinical features of subtype-specific orbital lymphoma. Design: Retrospective, interventional case series. Methods: The study included 7 international eye cancer centers. Patient data were collected from January 1, 1980 through December 31, 2017. A total of 797 patients with a histologically verified orbital lymphoma were included. The primary endpoints were overall survival, disease-specific survival, and progression-free survival. Results: The median age was 64 years, and 51% of patients (n = 407) were male. The majority of lymphomas were of B-cell origin (98%, n = 779). Extranodal marginal zone B-cell lymphoma (EMZL) was the most frequent subtype (57%, n = 452), followed by diffuse large B-cell lymphoma (DLBCL) (15%, n = 118), follicular lymphoma (FL) (11%, n = 91), and mantle cell lymphoma (MCL) (8%, n = 66). Localized Ann Arbor stage IE EMZL and FL were frequently treated with external beam radiation therapy. DLBCL, MCL, and disseminated EMZL and FL were primarily treated with chemotherapy. EMZL and FL patients had a markedly better prognosis (10-year disease-specific survival of 92% and 71%, respectively) than DLBCL and MCL patients (10-year disease-specific survival of 41% and 32%, respectively). Conclusions: Four lymphoma subtypes were primarily found in patients with orbital lymphoma: EMZL, DLBCL, FL, and MCL. The histologic subtype was found to be the main predictor for outcome, with EMZL and FL patients having a markedly better prognosis than DLBCL and MCL.
UR - http://www.scopus.com/inward/record.url?scp=85059153767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059153767&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2018.11.002
DO - 10.1016/j.ajo.2018.11.002
M3 - Article
C2 - 30419193
AN - SCOPUS:85059153767
SN - 0002-9394
VL - 199
SP - 44
EP - 57
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -